ARK believes the CRISPR market opportunity will be profound. In the near-term, ARK expects the first commercial CRISPR products will be for agricultural purposes, as it increases global food supply and enhances sustainability measures. In medicine, CRISPR’s addressable market in the monogenic disease space totals more than $75 billion annually.
This paper will elucidate the significance of genome-editing, the origins of CRISPR, how it works and how it compares to legacy genome-editing technologies. Then it examines CRISPR’s market opportunity across application areas and extrapolates the direct and indirect investable opportunities as a result of CRISPR technology. To read the full research report, please fill out the form and download ARK's white paper.
You also may be interested in our white paper: